Search Site:

Dexcel Pharma's R &D division is involved in all stages of the development of generic drugs - from the evaluation of patents, development of the formulation, validation, bio-equivalency and pharmakinectic studies (along with Phase I and Phase II clinical studies), to the submission of regulatory dossiers to the health authorities in Israel, Europe, United States and other countries.  Moreover, Dexcel Pharma has a unique and highly-qualified department dealing with Pharmacovigilance.  This department handles the reporting and documentation of side effects caused through use of the drug, in Israel and worldwide.